Foundation
Medicine FMI today announced that the discovery of a
novel and potentially clinically actionable oncogenic gene fusion in
lung cancer, NTRK1, using FoundationOne™, was published in the
current online edition of Nature Medicine1.
Lung cancer remains the leading cause of cancer-related death in men and
women in the United States2; however, the use of targeted
therapies in lung cancer has led to significant clinical benefit for
patients with EGFR mutations and ALK fusions. Therefore,
the identification of new, drug-sensitive oncogenes in this disease is
of great clinical interest and has the potential to expand treatment
options for patients.
“Our understanding of cancer complexity is increasing, and
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in